Description_x000D_ General description_x000D_ A disintegrin-like and metalloprotease with thrombospondin type 1 motif, 13 (ADAMTS13) also known as von willebrand factor-cleaving protease (VWFCP), has distinct regions like a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 domain and spacer domain rich in cysteine residues. ADAMST13 is highly expressed in the liver and secreted as an active enzyme in the blood. In human chromosome, the gene ADAMTS13 is localised on 9q34._x000D_ Physical form_x000D_ Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ A disintegrin-like and metalloprotease with thrombospondin type 13 (ADAMTS13) cleaves von Willebrand factor (VWF) and thereby controls platelet thrombus formation. ADAMTS13 requires zinc, and calcium for its effective catalytic activity. Mutations in ADAMTS13 can lead to life threatening acquired thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome. Congenital deficiency of ADAMTS13 leads to Upshaw−Schulman syndrome.